Repligen Corporation Lieferant von Life Science-To

Seite 1 von 1
neuester Beitrag: 21.08.20 11:19
eröffnet am: 30.03.12 13:34 von: macos Anzahl Beiträge: 16
neuester Beitrag: 21.08.20 11:19 von: Tamakoschy Leser gesamt: 7143
davon Heute: 4
bewertet mit 4 Sternen

30.03.12 13:34

2359 Postings, 4506 Tage macosRepligen Corporation Lieferant von Life Science-To

Cashflowpositiv, MK 180 Mio, Cash ca 35 Mio
Umsatz 2012 ca 50 Mio
Bei Zulassung SecreFlo(TM) im Juni winkt noch mal ein Umsatzschub..
Marktpotential 100 Mio in US.

EU und Japan soll Auslizenziert werden(noch kein Partner)  

11.04.12 22:01

2359 Postings, 4506 Tage macosRepligen: Catalysts For An Easy Double

21.04.12 15:16

2359 Postings, 4506 Tage macosOrencia Royalties

Orencia® (CTLA4-Ig) Royalties

CTLA4 is a key regulator of the activity of the immune system. CTLA4 “turns off” the immune system after it has successfully cleared a bacterial or viral infection by blocking the activation of T-cells, the immune cells responsible for initiating an immune response. CTLA4-Ig’s mechanism of action is different from the current therapies for autoimmune disease or organ transplant rejection, thus it may provide a treatment for patients who are refractory to existing therapies. In the 1990’s, our collaborators at the University of Michigan and the U.S. Navy demonstrated in animal models that a fusion protein consisting of fragments of CTLA4 and an antibody (“CTLA4-Ig”) could be used to treat certain autoimmune diseases. This research finding resulted in the granting of U.S. patent No. 6,685,941 (“the ‘941 Patent”) covering the treatment of certain autoimmune disorders including rheumatoid arthritis with CTLA4-Ig.

In December 2005, the FDA approved Bristol’s application to market CTLA4-Ig, under the brand name Orencia®, for treatment of rheumatoid arthritis. In January 2006, Repligen and the University of Michigan jointly filed a lawsuit against Bristol in the United States District Court for the Eastern District of Texas for infringement of the ‘941 Patent. In April 2008, Repligen and the University of Michigan entered into a settlement agreement with Bristol pursuant to which, Bristol made an initial payment of $5 million to Repligen and agreed to pay us royalties on the U.S. net sales of Orencia® for any clinical indication at a rate of 1.8% for the first $500 million of annual sales, 2.0% for the next $500 million and 4.0% of annual sales in excess of $1 billion for each year from January 1, 2008 until December 31, 2013.

The ‘941 Patent is owned by the University of Michigan and exclusively licensed to Repligen. In consideration of this exclusive license, Repligen agreed to pay the University of Michigan 15% of all royalty income received, after deducting legal expenses. There are no annual or other fees associated with this agreement. Under this agreement, since its inception through fiscal year 2009, Repligen has paid $1.1 million to the University of Michigan.  

21.04.12 15:53

2359 Postings, 4506 Tage macosAufgefächertes Dreieck

im Chart, mit allen Daten der letzten Jahre. Megaausbruch?  

25.04.12 13:05

2359 Postings, 4506 Tage macosPositive Results from Phase 1

Repligen Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy  

26.04.12 16:10

2359 Postings, 4506 Tage macosFDA cancels Advisory Committee meeting

Repligen Provides Regulatory Update for RG1068 New Drug Application; FDA Cancels Advisory Committee Meeting  

26.04.12 22:27

2072 Postings, 4975 Tage Joschi307Repligen Xetra

02.08.12 17:45

2359 Postings, 4506 Tage macosGute Zahlen heute

Cashberg wächst ca 39 Mille  

08.11.12 16:08

2359 Postings, 4506 Tage macosRepligen Reports Third Quarter 2012 Financial Resu

Repligen Reports Third Quarter 2012 Financial Results

- Net Income Triples on 94% Increase in Bioprocessing Product Sales -  

18.12.12 11:52

2359 Postings, 4506 Tage macosAus Seeking Alpha

Repligen wichtigste Geschäftsfeld ist die Herstellung von Protein A, welches verwendet wird, um monoklonale Antikörper während des Herstellungsprozesses zu reinigen. Repligen liefert über 95% des Weltmarktes.

kleiner Auszug von Diesem Herren  

09.01.13 15:18

2359 Postings, 4506 Tage macosLicensing Agreement with Pfizer

Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program  

   Antwort einfügen - nach oben

Online Brokerage über Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von!



Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln